medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2005, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2005; 3 (3)

Antibodies for systemic autoimmune diseases. Applications in dermatology. Part II

Miniño M

Language: Spanish
References: 65
Page: 261-271
PDF size: 387.53 Kb.


ABSTRACT

In this second part we comment some of the antibodies found in systemic lupus erythematosus, mixed connective disease, Sjögren syndrome, antiphospholipid syndrome, vasculitis, systemic scleroderma, poli/dermatomyositis, such as anti-Sm, U1 RNP, U2 RNP, anti-histones, cardiolipins, phosphatidilserine, P & C ANCA, anti-sintetase syndrome, anti-Scle-70, anti-Jo and rheumatoid factor, among others.


REFERENCES

  1. Burlingame RW. The clinical utility of antihistone antibodies. Clin Lab Med 1997; 17: 367-378

  2. Kalden JR, Gay S. Retroviruses and autoimmune rheumatic induction. The role of the immune response to microbial pathogens. Arthritis Rheum 1995; 38: 458-476

  3. Wilson W, Gharavi AE, Koike T, Lochsin MD, Branch DW, Piette JC et al. International consensus statement on preliminary classification criteria from definitive antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-1311.

  4. Cerón AL, Loubies MR, Correa GH. Manifestaciones cutáneas del síndrome anticuerpo antifosfolípido. Rev Chil Dermatol 2000; 16 (3): 192-196

  5. Barraza S, Estrella V, Leroux MB, Detarsio G, Taborda M, Bergero A. Síndrome anticuerpo antifosfolípido. ¿Cómo llegamos a su diagnóstico? Dermatol Argent 2000; 5: 342-349

  6. Leroux MB, Barraza S, Estrella V, Bearzotti M. Síndrome anticuerpo antifosfolípido. Arch Argen 2000; 50: 109-115

  7. Marini M, Rossi G, Magariños G. Síndrome antifosfolipídico: presentación de un caso y actualización del tema. Med Cut Iber Lat Am, 2002; 30: (3): 111-115

  8. Gibson GE, Su W, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol, 1997; 36: 970-982

  9. Nahass GT. Antiphospholipid antibodies and the antiphospholipid syndrome. JM Acad Dermatol 1997; 36: 149-168

  10. Robson KJ, Piette WW. “The presentation and differential diagnosis of cutaneous vascular occlusion syndromes”. In: James WD, Cockerell CB, Dzubow LM, Paller AS, Yancey KB (eds). Advances in dermatology. Mosby, St. Louis, 2000: 153-182

  11. Brandt J et al. Criteria for the diagnosis of lupus anticoagulants: An update on behalf of the subcommittee on Lupus Anticoagulant /Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190

  12. Colman R et al. Hemostasis and thrombosis: Basic principles and clinical practice. JB Lippincott Co., 3rd ed., Philadelphia 1994: 894-896

  13. Cowchock FS, Smith JB, and Gocial B. Antibodies to phospholipids and nuclear antigens in patients with repeated abortions. Am J Obstet Gynecol 1986; 155: 1002-1010

  14. Roussev RG, Kaider BD, Price DE, Coulam CB. Laboratory evaluation of women experiencing reproductive failure. Am J Reprod Immunol 1996; 35: 415-420

  15. Purvis MT, Kaider BD, Roussev RG, Coulam CB. Antinuclear antibody prevalence in patients with reproductive failure. Am J Reprod Immunol 1996; 35: 463

  16. Cortés-Hernández J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: A prospective study of 103 pregnancies. Human Reprod 2000: 13: 2345-2350

  17. Kaider BD, Coulam CB, Roussev RG. Murine embryos as a direct target for some human autoantibodies in vitro. Hum Reprod 1999; 10: 2556-2561

  18. Coulam CB. The role of antiphospholipid antibodies in reproduction: Questions answered and raised at the 18th Annual Meeting of the American Society of Reproductive Immunology. Am J Reprod Immunol 1999; 41: 1-4

  19. Reveille JD. The changing spectrum of rheumatic disease in human immunodeficiency virus infection. Semin Arthritis Rheum 2000; 30: 147-166

  20. Berman A, Espinoza LR, Díaz JD et al. Rheumatic manifestations of human immunodeficiency virus infection. Am J Med 1988; 85: 59-64

  21. Piette A. “Primary systemic vasculitis”. In: Sontheimer R, Provost T, (eds). Cutaneous manifestations of rheumatic diseases. Williams & Wilkins, Baltimore, 1996: 183

  22. Goeken JA. Antineutrophil cytoplasmic antibody: A useful serological marker for vasculitis. J Clin Immunol 1991; 11: 161

  23. Gibson LE, Specks U, Homburger H. Clinical utility of ANCA tests for the dermatologist. Intl J Dermatol 2003; 42 (11): 859-869

  24. Goeken JA. Antineutrophil citoplasmic and antiendothelial cell antibodies: New mechanisms for vasculitis. Curr Opin Dermatol 1995; 2: 75-82

  25. Specks U and Homburger HA. Anti-neutrophil cytoplasmic antibodies. Mayo Clin Proc 1994; 69: 1197-1198

  26. Jennette JC, Falk RJ. The coming of age of specific testing for anti-neutrophil cytoplasmic autoantibodies. Mayo Clin Proc 1994; 69: 908-910

  27. Gross WL, Schimtt WH, Csernok E. ANCA and associated diseases: Inmunodiagnostic and pathogenetic aspects. Clin Exp Immunol 1993; 91: 1-12

  28. Gal AA et al. The clinical and pathological spectrum of antineutrophil cytoplasmic autoantibody-related pulmonary disease. A comparison between perinuclear and cytoplasmic antineutrophil cytoplasmic autoantibodies. Arch Pathol Lab Med 1994; 118:1209-1214

  29. Cohen TJ et al. Prevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titer. The Lancet 1990; 336: 709-711

  30. De Remee RA et al. Lesions of the respiratory tract associated with the finding of anti-neutrophil cytoplasmic autoantibodies with a perinuclear staining pattern. Mayo Clin Proc 1994; 69: 819-824

  31. Jennette JC, Truttle R, Falk RJ. The clinical, serologic and immunohistologic heterogeneity of cutaneous leukoclastic angiitis. Adv Exp Med Biol 1993; 536: 323-326

  32. Targoff IN. Humoral immunity in polymyositis/dermatomyositis (Review). J Invest Dermatol 1993; 100: 1163-1170

  33. Targoff IN. Dermatomyositis and polymiositis. Curr Probl Dermatol 1991; 3: 130-135

  34. Targoff IN. Laboratory manifestations of polymiositis and dermatomyositis. Clin Dermatol 1988; 6: 60-79

  35. Arad-Dann H, Isenberg D, Ovadia E. Autoantibodies against a nuclear 56-kDa protein: A marker for inflammatory muscle disease. J Autoinmun 1989; 2: 875-880

  36. Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinic correlations and biologic significance (Review). Adv Dermatol 1992; 7: 3

  37. Love LA et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient group. Medicine 1991; 70:360-74.

  38. Bernstein R et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J 1984; 289: 151

  39. Yoshida S et al. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases: A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis and Rheum 1983; 26: 604

  40. Vázquez-Abad D, Rothfield NF. Sensitivity and specificity of Anti-Jo-1 antibodies in autoimmune diseases with myositis. Arthritis Rheum 1996; 39: 292-296

  41. Nishikal M, Ohya K, Kosaka M, Akiya K, Tojo T. Anti-Jo-1 antibodies in polymiositis: evaluation by ELISA using recombinant fusion protein Jo- 1 as antigen. Br J Rheumatol, 1998; 37: 357-361

  42. Takehara K et al. Antinuclear antibodies in the relatives of patients with systemic sclerosis. Br J Dermatol 1985; 112: 23

  43. Kipnis RJ et al. The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays. Arthritis Rheum 1990; 33: 1431-1437

  44. Jarzabek-Chorzeiska M et al. Scl-70 antibody: a specific marker of systemic sclerosis. Br J Dermatol 1986; 115: 393-401

  45. Reimer G. Autoantibodies against nuclear, nucleolar, and mitochondrial antigens in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1990; 16: 169-183

  46. Kuwana M, Pandey JP, Silver RM, Kawakami Y, Kaburaki J. HLA Class II Alleles in Systemic Sclerosis Patients with Anti-RNA Polymerase I/III Antibody: Associations with Subunit reactivities. J Rheumatol 2003; 30: 2392-2397

  47. Koopman WJ et al. Rheumatoid factor and human disease. Clin Immunol News 1990; 10: 137-141

  48. Eichenfield AH, Athreya BH, Doughty RA, Cebul RD. Utility of rheumatoid factor in the diagnosis of juvenile rheumatoid arthritis. Pediatrics 1986; 78: 480-484

  49. Shmerling RH, Delbanco TL. The rheumatoid factor: An analysis of clinical utility. Am J Med 1991; 91: 528-534

  50. Miyazaki M, Rndoh M, Juga T, Yabno N, Kuramoto T, Matsumoto Y et al. Rheumatoid factor and glomerulonephritis. Clin Exp Inmunol 1990; 81: 250-255

  51. Howard T, Iannore M, Burge J, Davis J. Rheumatoid factor, cryoglobulins, anti-DNA and renal disease in systemic lupus erythematosus. J Rheumatol 1991; 18: 826-830

  52. Cervera R, Khamashta A, Font T, Sebastián G, Gil A et al. Systemic lupus erythematosus: clinic and inmunological matters of disease expression in a cohort o 1000 patients. Medicine 1991; 72: 113-124

  53. Imanaka H, Takei S, Hokonohara M. Diagnostic value of anti-keratin antibodies in patients with juvenile rheumatoid arthritis. Japanese Journal of Rheumatology 1993; 4 (4): 217-290

  54. Schellekens GA, De Jong BA, Van der Hoogen FHJ, Van de Putte LA, Venrooij WJ. Citrulline is an Essential Constituent of Antigenic Determinants Recognized by Rheumatoid Arthritis-specific Autoantibodies. J Clin Invest 1998; 101 (1): 273-281

  55. Bas S, Perneger TV, Siets M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology 2002; 41: 809-814

  56. Bravo R, Frank R et al. Cyclin/PCNA is the auxiliary protein of DNA polymerase. Nature 1987; 326: 551

  57. Asero R, Origgi L, Crespi S et al. Autoantibody to proliferating cell nuclear antigen (PCNA) in SLE: A clinical and serological study. Clin Exp Rheumatol 1987; 5: 241-246

  58. Elkon KB, Bonfa E, Weissbach H, Brot N. Anti-ribosomal antibodies in SLE, infection, and following deliberate immunisation. Advances Exp Med Biol 1994; 347: 81-92

  59. Takeda I, Rayna K, Mavafagh F, Wolfson-Reichlin M, Reichlin M. Dual binding capabilities of anti-double-stranded DNA antibodies and antiribosomal phosphoprotein (P) antibodies. Lupus 2001; 10 (12): 857-865

  60. Reichlin M, Wolfson-Reichlin M. Correlations of anti-dsDNA and anti-ribosomal P autoantibodies with lupus nephritis. Clin Immunol 2003; 108: 69-72

  61. Sun KH, Tang SJ, Lin ML, Wang YS, Wang GH, Liu WT. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatol 2001; 40: 750-756

  62. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998; 37: 15-20

  63. Franceschini F, Cavazzana I, Generali D, Quinzanini M, Viardi L, Ghirardello A, Doria A, Cattaneo R. Anti-Ku Antibodies in Connective Tissue Diseases: Clinical and Serological Evaluation of 14 Patients. J Rheumatol 2002; 29: 1393-1397

  64. Targoff I. Idiopathic Inflammatory Myopathy: Autoantibody Update. Curr Rheumatol Rep 2002, 4: 434-441

  65. Brouwer R, Vree Egberts W, Hengstman G, Raijmakers R, Van Engelen R, Seelig H, Renz M, Mierau M, Genth E, Pruijn G, Van VenrooijW. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Research 2002, 4: 134-138




2020     |     www.medigraphic.com